Botox competitor “Reloxin” (sold in Europe as “Dysport”) received its FDA approval today.
The FDA decided to approve both the cosmetic indications (for wrinkles) and the functional indications (cervical dystonia) at the same time – and decided that the drug should be sold under the same name for both categories. So, it’s now officially “Dysport” – just like in Europe.
We’re waiting for details to be released about the pricing, marketing incentives – such as potential combinations with Medicis’ line of fillers, and so forth. These details will be key to the success or failure of the product, I believe.
The next 6 months should prove to be very interesting, to see how pharma giant Allergan responds to the “new kid on the block”. I’m expecting sparks to fly!!